Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06714955 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects
A Phase 1 study, sponsored by BrightGene Bio-Medical Technology Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT06714955: Completed Phase 1 study, sponsored by BrightGene Bio-Medical Technology Co..
NCT06714955 is a Phase 1 study that has completed, run by BrightGene Bio-Medical Technology Co.. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06714955, a Phase 1 study, has completed, sponsored by BrightGene Bio-Medical Technology Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 1, double-blind, parallel-arm ,placebo-controlled study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), safety and tolerability of BGM0504 following multiple subcutaneous (SC) administrations in non-diabetic overweight or obese adult subjects.
Interventions
- DRUG Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
- DRUG Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
- DRUG Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2025-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06714955
The ClinicalTrials.gov registry entry for NCT06714955 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The listed sponsor is BrightGene Bio-Medical Technology Co., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week. is the first listed.
NCT06714955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06714955 about?
NCT06714955 is a clinical study titled "Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects". This is a Phase 1, double-blind, parallel-arm ,placebo-controlled study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), safety and tolerability of BGM0504 following multiple subcutaneous (SC) administrations in non-diabetic overweight or obese adult subjects.
What is the current status of trial NCT06714955?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-10-21. Estimated completion is 2025-03-03.
What interventions are being tested in trial NCT06714955?
The interventions under investigation include: Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week. (DRUG), Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week. (DRUG), Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week. (DRUG).
Who is sponsoring clinical trial NCT06714955?
This trial is sponsored by BrightGene Bio-Medical Technology Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.